E.1 Medical condition or disease under investigation |
E.1.1 | Medical condition(s) being investigated |
Mild cognitive impairment (MCI) or mild dementia, both of the Alzheimer's type. |
Decadimento cognitivo lieve (MCI) o demenza lieve, entrambi del tipo Alzheimer. |
|
E.1.1.1 | Medical condition in easily understood language |
Early Alzheimer's disease. |
Morbo di Alzheimer in fase iniziale. |
|
E.1.1.2 | Therapeutic area | Diseases [C] - Nervous System Diseases [C10] |
MedDRA Classification |
E.1.2 Medical condition or disease under investigation |
E.1.2 | Version | 20.0 |
E.1.2 | Level | LLT |
E.1.2 | Classification code | 10001896 |
E.1.2 | Term | Alzheimer's disease |
E.1.2 | System Organ Class | 100000004852 |
|
E.1.3 | Condition being studied is a rare disease | No |
E.2 Objective of the trial |
E.2.1 | Main objective of the trial |
To confirm the superiority of oral semaglutide versus placebo on the change in cognition and function in subjects with mild cognitive impairment (MCI) or mild dementia, both of the Alzheimer's type. |
Confermare la superiorità di semaglutide orale in confronto al placebo sulla variazione nella capacità cognitiva e nella funzione in soggetti affetti da MCI o demenza lieve, entrambi del tipo Alzheimer. |
|
E.2.2 | Secondary objectives of the trial |
To compare the effects of oral semaglutide versus placebo in subjects with MCI or mild dementia, both of the Alzheimer's type, on: - progression to dementia among subjects with MCI at baseline - neuropsychiatric symptoms - safety and tolerability - quality of life |
Confrontare gli effetti di semaglutide orale in confronto al placebo nei soggetti affetti da MCI o demenza lieve, entrambi del tipo Alzheimer su: -progressione verso la demenza tra i soggetti affetti da MCI al basale -sintomi neuropsichiatrici -sicurezza e tollerabilità -qualità della vita |
|
E.2.3 | Trial contains a sub-study | No |
E.3 | Principal inclusion criteria |
- Male or female, aged 55-85 years (both inclusive) at the time of signing informed consent. - MCI or mild dementia of the Alzheimer's type according to the National Institute of Aging-Alzheimer's Association (NIA-AA) 2018 criteria. - Clinical Dementia Rating (CDR) global score of 0.5 and CDR of 0.5 or more in at least one of the three instrumental activities of daily living categories (personal care, home & hobbies, community affairs) Or CDR global score of 1.0. - Repeatable Battery for the Assessment of Neuropsychological Status (RBANS) delayed memory index score of less than or equal to 85. - Mini-Mental State Examination (MMSE) greater than or equal to 22. - Amyloid positivity established with either amyloid positron emission tomography (PET) or cerebrospinal fluid (CSF) Aß1-42. - If receiving an approved Alzheimer's disease treatment (such as acetylcholinesterase inhibitors or memantine) the dose must have been stable for at least 3 months prior to screening and should not be changed during the trial unless medically necessary |
- Maschi o femmine, età 55-85 anni (estremi compresi) al momento della firma del modulo di consenso informato. - MCI o demenza lieve del tipo Alzheimer secondo i criteri del National Institute of Aging-Alzheimer's Association (NIA-AA) 2018. - Punteggio Clinical Dementia Rating (CDR) globale pari a 0,5 e CDR pari a 0,5 o superiore in almeno una delle tre attività strumentali della vita quotidiana (cura della persona, casa e hobby, affari comunitari) Oppure Punteggio globale CDR pari a 1,0 - Punteggio dell’indice di memoria ritardato Repeatable Battery for the Assessment of Neuropsychological Status (RBANS) minore o uguale a 85 - Mini-Mental State Examination (MMSE) maggiore o uguale a 22 - Positività all’amiloide stabilita con tomografia ad emissione di positroni (PET) amiloide o con fluido cerebrospinale (CSF) Aß1-42 - Se si riceve un trattamento approvato per il morbo di Alzheimer (come gli inibitori dell’acetilcolinesterasi o la memantina), la dose deve essere rimasta stabile per almeno 3 mesi prima dello screening e non deve essere modificata durante lo studio, a meno che non sia necessario da un punto di vista medico. |
|
E.4 | Principal exclusion criteria |
- Brain magnetic resonance imaging (MRI) (or computerised tomography (CT)) scan suggestive of clinically significant structural central nervous system (CNS) disease confirmed by central read (e.g. cerebral large vessel disease [large vessel (cortical) infarcts greater than 10 mm in diameter], prior macro-haemorrhage [ greater than 1 cm^3], cerebral vascular malformations, cortical hemosiderosis, intracranial aneurism(s), intracranial tumours, changes suggestive of normal pressure hydrocephalus). - Brain MRI (or CT) scan suggestive of strategic infarcts defined as bilateral thalamic lacunar infarcts and singular paramedian thalamic infarcts confirmed by central read. - Evidence of a relevant neurological disorder other than mild cognitive impairment (MCI) or mild dementia of the Alzheimer's type at screening, including but not limited to Parkinson's disease, Lewy body disease, frontotemporal dementia of any type, Huntington's disease, amyotrophic lateral sclerosis, multiple sclerosis, systemic lupus erythematosus, progressive supranuclear palsy, neurosyphilis, human immunodeficiency virus (HIV), learning disability, intellectual disability, hypoxic cerebral damage, or significant head trauma with loss of consciousness that led to persistent cognitive deficits. - Evidence of a clinically relevant or unstable psychiatric disorder, based on Diagnostic and Statistical Manual of Mental Disorders (DSM–5) criteria, including schizophrenia or other psychotic disorder, or bipolar disorder. A subject with a history of major depression who has not had an episode in the last 24 months before the day of screening and is considered in remission or whose depression is controlled with treatment can be included in the trial per investigator's judgement. |
- Malattia strutturale, clinicamente significativa del Sistema Nervoso Centrale (CNS) evidenziata da Risonanza Magnetica Nucleare (MRI) (o tomografia computerizzata - CT), confermata da lettura centrale (ad es. malattia cerebrale dei grandi vasi [infarti dei grandi vasi (corticali) maggiore di 10 mm di diametro], precedente macro-emorragia [maggiore di 1 cm3], malformazioni vascolari cerebrali, emosiderosi corticale, anerurismi intracranici, tumori intracranici, alterazioni attribuibili a idrocefalo normoteso). - Infarti strategici definiti come infarti talamici lacunari bilaterali e infarti talamici paramediani singoli evidenziati da MRI cerebrale (o CT) confermati da lettura centrale. - Evidenze di un disturbo neurologico rilevante diverso dal decadimento cognitivo lieve (MCI) o dalla demenza lieve di tipo Alzheimer allo screening, come a titolo di esempio, ma non limitato a morbo di Parkinson, malattia dei corpi di Lewy, demenza frontotemporale di qualsiasi tipo, malattia di Huntington, sclerosi laterale amiotrofica, sclerosi multipla, lupus eritematoso sistemico, paralisi sopranucleare progressiva, neurosifilide, virus umano dell'immunodeficienza (HIV), disturbi dell’apprendimento, disabilità intellettiva, danno cerebrale ipossico, o trauma cranico significativo con perdita di conoscenza che ha portato a deficit cognitivi persistenti. - Evidenze di un disturbo psichiatrico clinicamente rilevante o instabile, in base ai criteri del Manuale diagnostico e statistico dei disturbi mentali (Diagnostic and Statistical Manual of Mental Disorders, DSM–5), compresa la schizofrenia o un altro disturbo psicotico o bipolare. Un soggetto con una storia di depressione grave, che non ha avuto un episodio negli ultimi 24 mesi prima del giorno dello screening ed è considerato in remissione, o la cui depressione è controllata con il trattamento, può essere incluso nello studio secondo il giudizio dello sperimentatore. |
|
E.5 End points |
E.5.1 | Primary end point(s) |
Change in the Clinical Dementia Rating – Sum of Boxes (CDR-SB) score |
Variazione nella valutazione clinica della demenza - Somma del punteggio delle caselle (Clinical Dementia Rating – Sum of Boxes, CDR-SB) |
|
E.5.1.1 | Timepoint(s) of evaluation of this end point |
From baseline (week 0) to week 104 |
Dal basale (settimana 0) alla settimana 104 |
|
E.5.2 | Secondary end point(s) |
1. Change in the Alzheimer's Disease Cooperative Study Activities of Daily Living Scale for mild cognitive impairment (MCI) (ADCS-ADL-MCI) score 2. Time to progression to dementia (CDR global greater than or equal to 1.0) among subjects with MCI (CDR global equal to 0.5) at baseline 3. Change in the 13-item Alzheimer's Disease Assessment Scale – Cognitive Subscale (ADAS-Cog-13) score 4. Change in the Montreal Cognitive Assessment (MoCA) score 5. Change in the Alzheimer's Disease Composite Score (ADCOMS) 6. Change in the Mini-Mental State Examination (MMSE) score 7. Change in the 10-item Neuropsychiatric Inventory (NPI) score 8. Time to progression in disease stage based on global CDR score 9. Number of treatment emergent adverse events (TEAEs) 10. Change in high sensitivity C-reactive protein level 11. Time to first occurrence of major adverse cardiovascular event (MACE) comprising non-fatal myocardial infarction, non-fatal stroke and all-cause death 12. Time to first occurrence of stroke 13. Change in the EQ-5D-5L proxy score Extension phase 14. Change in the CDR-SB score 15. Change in the ADCS-ADL-MCI total score 16. Time to progression to dementia (CDR global greater than or equal to 1.0) among subjects with MCI (CDR global equal to 0.5) at baseline |
1. Variazione nel punteggio della scala Alzheimer’s Disease Cooperative Study Activities of Daily Living Scale per il decadimento cognitivo lieve (MCI) (ADCS-ADL-MCI) 2. Tempo di progressione verso la demenza (CDR globale magiore o uguale a 1,0) tra i soggetti con MCI (CDR globale = 0,5) al basale 3. Variazione del punteggio nella scala 13-item Alzheimer’s Disease Assessment Scale – Cognitive Subscale (ADAS-Cog-13) 4. Variazione nel punteggio del test Montreal Cognitive Assessment (MoCA) 5. Variazione nel punteggio Alzheimer’s Disease Composite Score (ADCOMS) 6. Variazione nel punteggio del Mini-Mental State Examination (MMSE) 7. Variazione nel punteggio 10-item Neuropsychiatric Inventory (NPI) 8. Tempo di progressione negli stadi della malattia in base al punteggio CDR globale 9. Numero degli eventi avversi emergenti dal trattamento (Treatment Emergent Adverse Events, TEAEs) 10. Variazione nel livello di proteina C-reattiva 11. Tempo prima del primo evento avverso cardiovascolare maggiore (Major Adverse Cardiovascular Event, MACE), tra cui infarto del miocardico non fatale, ictus non fatale e decesso per qualsiasi causa 12. Tempo prima del primo episodio di ictus 13. Variazione del punteggio della scala EQ-5D-5L Fase di estensione 14. Variazione nel punteggio CDR-SB 15. Variazione nel punteggio totale ADCS-ADL-MCI 16. Tempo di progressione verso la demenza (CDR globale maggiore o uguale a 1,0) tra i soggetti con MCI (CDR globale = 0,5) al basale |
|
E.5.2.1 | Timepoint(s) of evaluation of this end point |
1.-13 From baseline (week 0) to week 104 14.-16. From baseline (week 0) to week 156 |
1.-13 Dal basale (settimana 0) alla settimana 104 14.-16. Dal basale (settimana 0) alla settimana 156 |
|
E.6 and E.7 Scope of the trial |
E.6 | Scope of the trial |
E.6.1 | Diagnosis | No |
E.6.2 | Prophylaxis | No |
E.6.3 | Therapy | No |
E.6.4 | Safety | Yes |
E.6.5 | Efficacy | Yes |
E.6.6 | Pharmacokinetic | No |
E.6.7 | Pharmacodynamic | No |
E.6.8 | Bioequivalence | No |
E.6.9 | Dose response | No |
E.6.10 | Pharmacogenetic | No |
E.6.11 | Pharmacogenomic | No |
E.6.12 | Pharmacoeconomic | No |
E.6.13 | Others | Yes |
E.6.13.1 | Other scope of the trial description |
Tolerability |
Tollerabilità |
|
E.7 | Trial type and phase |
E.7.1 | Human pharmacology (Phase I) | No |
E.7.1.1 | First administration to humans | No |
E.7.1.2 | Bioequivalence study | No |
E.7.1.3 | Other | No |
E.7.1.3.1 | Other trial type description | |
E.7.2 | Therapeutic exploratory (Phase II) | No |
E.7.3 | Therapeutic confirmatory (Phase III) | Yes |
E.7.4 | Therapeutic use (Phase IV) | No |
E.8 Design of the trial |
E.8.1 | Controlled | Yes |
E.8.1.1 | Randomised | Yes |
E.8.1.2 | Open | No |
E.8.1.3 | Single blind | No |
E.8.1.4 | Double blind | Yes |
E.8.1.5 | Parallel group | Yes |
E.8.1.6 | Cross over | No |
E.8.1.7 | Other | No |
E.8.2 | Comparator of controlled trial |
E.8.2.1 | Other medicinal product(s) | No |
E.8.2.2 | Placebo | Yes |
E.8.2.3 | Other | No |
E.8.2.4 | Number of treatment arms in the trial | 2 |
E.8.3 |
The trial involves single site in the Member State concerned
| No |
E.8.4 | The trial involves multiple sites in the Member State concerned | Yes |
E.8.4.1 | Number of sites anticipated in Member State concerned | 9 |
E.8.5 | The trial involves multiple Member States | Yes |
E.8.5.1 | Number of sites anticipated in the EEA | 152 |
E.8.6 Trial involving sites outside the EEA |
E.8.6.1 | Trial being conducted both within and outside the EEA | Yes |
E.8.6.2 | Trial being conducted completely outside of the EEA | Information not present in EudraCT |
E.8.6.3 | If E.8.6.1 or E.8.6.2 are Yes, specify the regions in which trial sites are planned |
Australia |
Brazil |
Canada |
China |
Israel |
Japan |
Korea, Republic of |
Russian Federation |
Serbia |
South Africa |
Taiwan |
Turkey |
Ukraine |
United States |
Austria |
Belgium |
Bulgaria |
Croatia |
Denmark |
Finland |
France |
Germany |
Greece |
Hungary |
Ireland |
Italy |
Netherlands |
Norway |
Poland |
Portugal |
Romania |
Slovakia |
Slovenia |
Spain |
Sweden |
Switzerland |
United Kingdom |
Czechia |
Argentina |
|
E.8.7 | Trial has a data monitoring committee | Yes |
E.8.8 |
Definition of the end of the trial and justification where it is not the last
visit of the last subject undergoing the trial
|
|
E.8.9 Initial estimate of the duration of the trial |
E.8.9.1 | In the Member State concerned years | 4 |
E.8.9.1 | In the Member State concerned months | 3 |
E.8.9.1 | In the Member State concerned days | 28 |
E.8.9.2 | In all countries concerned by the trial years | 4 |
E.8.9.2 | In all countries concerned by the trial months | 3 |
E.8.9.2 | In all countries concerned by the trial days | 28 |